Mm Samama

Summary

Publications

  1. ncbi request reprint Synthetic direct and indirect factor Xa inhibitors
    Meyer Michel Samama
    Hotel Dieu University Hospital, Paris, France
    Thromb Res 106:V267-73. 2002
  2. doi request reprint Newer anticoagulants in 2009
    Meyer Michel Samama
    Hotel Dieu University Hospital, 1, Place du Parvis Notre Dame, 75181 Paris Cedex 04, France
    J Thromb Thrombolysis 29:92-104. 2010
  3. doi request reprint [Hemorrhagic accidents of the new oral anticoagulants and coagulation assays]
    M M Samama
    Service d Hematologie Biologique, Groupe Hospitalier Broca Cochin Hôtel Dieu, 27, rue du Faubourg Saint Jacques, 75679 Paris Cedex 14, France
    J Mal Vasc 38:259-70. 2013
  4. doi request reprint Monitoring plasma levels of factor Xa inhibitors: how, why and when?
    Meyer Michel Samama
    Biomnis Laboratory, Ivry sur Seine, Paris, France
    Expert Rev Hematol 6:155-64. 2013
  5. doi request reprint Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopedic surgery: an observational study
    Meyer Michel Samama
    Cochin Broca Hôtel Dieu University Hospital, Paris, France
    J Thromb Thrombolysis 35:140-6. 2013
  6. doi request reprint Do new oral anticoagulants require laboratory monitoring? The clinician point of view
    Meyer Michel Samama
    Cochin Broca Hôtel Dieu University Hospital, Paris, France
    Thromb Res 130:S88-9. 2012
  7. doi request reprint In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux
    Meyer Michel Samama
    Haematology Department, Hotel Dieu University Hospital, Paris, France
    Thromb Res 129:e77-82. 2012
  8. doi request reprint Evaluation of the prothrombin time for measuring rivaroxaban plasma concentrations using calibrators and controls: results of a multicenter field trial
    Meyer Michel Samama
    Hotel Dieu University Hospital, Paris, France
    Clin Appl Thromb Hemost 18:150-8. 2012
  9. doi request reprint Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls
    Meyer Michel Samama
    Hotel Dieu University Hospital, Paris, France
    Thromb Haemost 107:379-87. 2012
  10. doi request reprint Laboratory assessment of new anticoagulants
    Meyer M Samama
    Hotel Dieu University Hospital, Paris, France
    Clin Chem Lab Med 49:761-72. 2011

Detail Information

Publications19

  1. ncbi request reprint Synthetic direct and indirect factor Xa inhibitors
    Meyer Michel Samama
    Hotel Dieu University Hospital, Paris, France
    Thromb Res 106:V267-73. 2002
  2. doi request reprint Newer anticoagulants in 2009
    Meyer Michel Samama
    Hotel Dieu University Hospital, 1, Place du Parvis Notre Dame, 75181 Paris Cedex 04, France
    J Thromb Thrombolysis 29:92-104. 2010
    ..Their use in the general world will hopefully confirm the promising results of clinical trials...
  3. doi request reprint [Hemorrhagic accidents of the new oral anticoagulants and coagulation assays]
    M M Samama
    Service d Hematologie Biologique, Groupe Hospitalier Broca Cochin Hôtel Dieu, 27, rue du Faubourg Saint Jacques, 75679 Paris Cedex 14, France
    J Mal Vasc 38:259-70. 2013
    ..Some suggestions for the management of patients with bleeding have been published but there is still little clinical evidence for these interventions. ..
  4. doi request reprint Monitoring plasma levels of factor Xa inhibitors: how, why and when?
    Meyer Michel Samama
    Biomnis Laboratory, Ivry sur Seine, Paris, France
    Expert Rev Hematol 6:155-64. 2013
    ..The physicians must be aware of the possibility to measure the plasma concentration of FXa inhibitors in patients at high risk of bleeding and in several other special clinical situations...
  5. doi request reprint Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopedic surgery: an observational study
    Meyer Michel Samama
    Cochin Broca Hôtel Dieu University Hospital, Paris, France
    J Thromb Thrombolysis 35:140-6. 2013
    ..An interference by pantoprazole, a drug which reduces dabigatran absorption, could explain the observed lower than expected results...
  6. doi request reprint Do new oral anticoagulants require laboratory monitoring? The clinician point of view
    Meyer Michel Samama
    Cochin Broca Hôtel Dieu University Hospital, Paris, France
    Thromb Res 130:S88-9. 2012
    ..Trials are needed to determine the relationship of assay results with bleeding or thrombotic complications. Pros and Cons laboratory measurements are discussed...
  7. doi request reprint In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux
    Meyer Michel Samama
    Haematology Department, Hotel Dieu University Hospital, Paris, France
    Thromb Res 129:e77-82. 2012
    ..Secondary objectives included evaluation of edoxaban and inhibition of coagulation parameters (prothrombin time [PT], activated partial thromboplastin time [aPTT]), anti-FXa activity and clotting times...
  8. doi request reprint Evaluation of the prothrombin time for measuring rivaroxaban plasma concentrations using calibrators and controls: results of a multicenter field trial
    Meyer Michel Samama
    Hotel Dieu University Hospital, Paris, France
    Clin Appl Thromb Hemost 18:150-8. 2012
    ..The widely available PT assay, in conjunction with rivaroxaban calibrators, may be useful for the measurement of peak plasma levels of rivaroxaban...
  9. doi request reprint Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls
    Meyer Michel Samama
    Hotel Dieu University Hospital, Paris, France
    Thromb Haemost 107:379-87. 2012
    ....
  10. doi request reprint Laboratory assessment of new anticoagulants
    Meyer M Samama
    Hotel Dieu University Hospital, Paris, France
    Clin Chem Lab Med 49:761-72. 2011
    ..The tests show variations in response to anticoagulants - some of which have clinical relevance. Thus, it is important to be aware of the observed variations in order to prevent the misinterpretation of test results...
  11. doi request reprint The mechanism of action of rivaroxaban--an oral, direct Factor Xa inhibitor--compared with other anticoagulants
    Meyer Michel Samama
    Hotel Dieu University Hospital, Paris, France
    Thromb Res 127:497-504. 2011
    ..Although the mechanism of action differs between the direct Factor Xa and direct thrombin inhibitors, phase III studies of these new agents confirmed that both Factor Xa and thrombin are viable anticoagulation targets...
  12. doi request reprint Comparison of a direct Factor Xa inhibitor, edoxaban, with dalteparin and ximelagatran: a randomised controlled trial in healthy elderly adults
    Meyer M Samama
    Biomnis, 78 Avenue de Verdun, 94208 Ivry sur Seine Cedex, France
    Thromb Res 126:e286-93. 2010
    ..Edoxaban (the free base of DU-176b) is a new, oral direct Factor Xa inhibitor. This is the first study to compare the hemostatic response to edoxaban, ximelagatran, and dalteparin in healthy, elderly adults...
  13. doi request reprint [Perioperative use of antithrombotic agents: recommendations of the American College of Chest Physicians (ACCP) and the French Superior Health Authority (HAS)]
    M M Samama
    Groupe interdisciplinaire Trousseau sur les antithrombotiques, Unité hémostase thrombose, Hotel Dieu, Parvis Notre Dame, 75181 Paris Cedex 04, France
    J Mal Vasc 35:220-34. 2010
    ..Grade 2 recommendations are considered to be suggestions. They imply that the individual physician chooses between different therapeutic strategies. For the purpose of this work, the most important recommendations are the following:..
  14. doi request reprint Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor
    Meyer Michel Samama
    Hotel Dieu University Hospital, Paris, France 2Biomnis Laboratory, Ivry sur Seine, France
    Thromb Haemost 103:815-25. 2010
    ..Finally, all clotting and chromogenic assays showed a concentration-dependent effect induced by rivaroxaban...
  15. doi request reprint [From old to new anticoagulants: the role of the biologist]
    Mm Samama
    Laboratoire Biomnis, 78, avenue de Verdun, 94200 Ivry sur Seine
    Ann Biol Clin (Paris) 67:525-34. 2009
    ..Both do not require routine laboratory monitoring. However, coagulation assays for measuring their activity have been studied. A small number of standardized tests should be perfected...
  16. doi request reprint Is the inhibition of both clot-associated thrombin and factor Xa more clinically relevant than either one alone?
    Sadia Meddahi
    Service d Hematologie Biologique, Hotel Dieu, Paris, France
    Blood Coagul Fibrinolysis 20:207-14. 2009
    ....
  17. doi request reprint Clinical studies with anticoagulants to improve survival in cancer patients
    Grigoris T Gerotziafas
    EA3499, Faculty of Medicine, University Pierre and Marie Curie Paris VI, Paris, France
    Pathophysiol Haemost Thromb 36:204-11. 2008
    ..The forthcoming clinical trials have to address some issues regarding the optimal dose, the timing and the duration of treatment with LMWH in relation to chemotherapy or other anticancer therapies...
  18. ncbi request reprint Standard measurement of clot-bound thrombin by using a chromogenic substrate for thrombin
    Sadia Meddahi
    Service d Hematologie Biologique, Hopital Hotel Dieu, Paris, France
    Thromb Res 114:51-6. 2004
    ..We suggest that clot-bound thrombin can be measured using a chromogenic substrate specific for thrombin under our experimental condition...